Search Menu
Photonics Media Photonics Buyers' Guide Photonics EDU Photonics Spectra BioPhotonics EuroPhotonics Industrial Photonics Photonics Showcase Photonics ProdSpec Photonics Handbook
More News
Email Facebook Twitter Google+ LinkedIn Comments

Photonic Material Helps Track Cancer Drug's Progress
Sep 1999
BUFFALO, N.Y., Sept. 29 -- Researchers at the University at Buffalo and Tulane University have tracked in real time the path traveled by a cancer drug linked to a peptide hormone carrier as it is taken up by a human breast-cancer cell.
As reported in the Proceedings of the National Academy of Sciences, the research demonstrates how new photonic materials developed at Buffalo have allowed scientists to image the cellular pathway of AN-152, a combination of the commonly prescribed chemotherapeutic agent doxorubicin linked to a luteinizing hormone-release hormone analog that makes the compound specific to such cancers as those of the ovary, breast, cervix and prostate. The scientists were able to track this compound through a human breast-cancer cell by combining it with a fluorescent probe (C625) synthesized in the laboratory of Paras Prasad, the executive director of Buffalo's Institute for Lasers, Photonics and Biophotonics, where the experimental work was conducted.

News & Features

Terms & Conditions Privacy Policy About Us Contact Us
back to top
Facebook Twitter Instagram LinkedIn YouTube RSS
©2019 Photonics Media, 100 West St., Pittsfield, MA, 01201 USA,

Photonics Media, Laurin Publishing
x We deliver – right to your inbox. Subscribe FREE to our newsletters.
We use cookies to improve user experience and analyze our website traffic as stated in our Privacy Policy. By using this website, you agree to the use of cookies unless you have disabled them.